(Corrects to $3.9 billion from $2.9 billion in paragraph 3)
Jan 26 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved French drugmaker Advanced Accelerator Application SA’s drug to treat patients with a type of digestive tract cancer.
The FDA said the drug, Lutathera, was approved to treat a type of cancer affecting a gastrointestinal tract.
Swiss biotech Novartis AG agreed in October to buy Advanced Accelerator in a $3.9 billion deal. (Reporting by Manas Mishra in Bengaluru; editing by Sai Sachin Ravikumar)